We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Naratriptan for the treatment of acute migraine: meta-analysis of randomised controlled trials (No conflict of interest was declared.).
- Authors
Darren M. Ashcroft; David Millson
- Abstract
To evaluate the comparative efficacy and tolerability of naratriptan in the treatment of acute attacks of migraine. Meta-analysis of randomised controlled trials using a random effects model. A total of 4499 patients suffering from moderate or severe attacks of acute migraine reported in ten trials. Response rate ratios for headache relief, pain-free response and sustained relief (424 hours). Adverse events were estimated with the rate ratio (RR), risk difference and number needed to harm. Pooled RRs relative to placebo for pain-free response at 2 and 4 hours for naratriptan 2.5 mg were 2.52 (95% CI: 1.783.57) and 2.58 (1.993.35). Naratriptan 2.5 mg was more effective than naratriptan 1 mg; the corresponding RRs for pain-free response at 2 and 4 hours were 1.54 (95% CI: 1.281.86) and 1.35 (1.201.51). In contrast, naratriptan 2.5 mg was less effective in pain-free response than either rizatriptan 10 mg at 4 hours (RR: 0.68; 95% CI: 0.550.85) or sumatriptan 100 mg at 4 hours (RR: 0.79; 95% CI: 0.670.93). However, significantly fewer patients experienced adverse effects with naratriptan 2.5 mg than with rizatriptan 10 mg (RR: 0.73; 95% CI: 0.560.97) or sumatriptan 100 mg (RR: 0.68; 95% CI: 0.550.86). Naratriptan is an effective and well-tolerated treatment for acute attacks of migraine. Head-to-head comparisons suggest that naratriptan 2.5 mg is significantly more effective than the 1 mg dose. Rizatriptan 10 mg and sumatripatn 100 mg were superior to naratriptan in terms of headache relief, while zolmitriptan 2.5 mg seemed to have comparable efficacy. Randomised controlled trials have shown that at licensed doses (1 and 2.5 mg), naratriptan is associated with a lower incidence of adverse effects than rizatriptan, sumatriptan and zolmitriptan. The incidence rates of adverse effects were similar to placebo. Copyright © 2003 John Wiley & Sons, Ltd.
- Subjects
MIGRAINE; HEADACHE treatment; THERAPEUTICS; SUMATRIPTAN; VASOCONSTRICTORS; DRUG therapy
- Publication
Pharmacoepidemiology & Drug Safety, 2004, Vol 13, Issue 2, p73
- ISSN
1053-8569
- Publication type
Article
- DOI
10.1002/pds.890